Penumbra, Inc.
PEN
株式のランク
#1679
Penumbra, Inc., together with its subsidiaries, designs, develops,... Penumbra, Inc., together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. It offers computer-assisted vacuum thrombectomy; peripheral thrombectomy products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX. It also provides access products, including guide catheters and the Penumbra distal delivery catheters under the Neuron, Neuron MAX, BENCHMARK, BMX, DDC, Access25; MIDWAY, and PX SLIM brands; Penumbra System, an integrated mechanical thrombectomy system comprising reperfusion catheters and separators, the 3D Revascularization device, aspiration tubing, aspiration pump, and other components and accessories under the Penumbra RED, SENDit, JET, ACE, BMX, Max, 3D Revascularization Device, and Penumbra ENGINE brands; and neuro embolization coiling systems that include the Penumbra Coil 400, for the treatment of aneurysms and other complex lesions, detachable coils of neurovascular lesions under the Penumbra SMART COIL, SwiftSET, and Penumbra SwiftPAC Coil brands; and POD400 and PAC400 brands. In addition, it provides peripheral embolization products, such as Ruby Embolization Platform, which consists of detachable coils for peripheral applications; Ruby LP and XL Embolization Platform; Penumbra LANTERN Delivery Microcatheter, a low-profile microcatheter with a high-flow lumen; POD (Penumbra Occlusion Device) System, a single device solution; Packing Coil LP; and Packing Coil, a complementary device for use in other peripheral embolization products. Further, it offers neurosurgical tools comprising the Artemis Neuro Evacuation Device for surgical removal of fluid and tissue from the ventricles and cerebrum. It sells its products through direct sales organizations and distributors. The company was incorporated in 2004 and is based in Alameda, California.
株価
$324.07
時価総額
$12.76B
変化（1日）
0.40%
変化（1年）
30.87%
国
US
取引 Penumbra, Inc. (PEN)
カテゴリー
Healthcare
Penumbra, Inc.（PEN）のP/E比率
October 2026 時点のP/E比率 TTM 78.27
Penumbra, Inc. の最新の財務報告および株価によると、現在の P/E (TTM) は 78.27 です。2023 年末時点での P/E は 106.20 でした。
Penumbra, Inc. の P/E 比率の履歴（2012 〜 2026）
各年末のP/E比率
| 年 | P/E比率 | 変化 |
|---|---|---|
| 2026 (TTM) | 78.27 | -88.05% |
| 2024 | 654.78 | 516.55% |
| 2023 | 106.20 | -102.53% |
| 2022 | -4.20K | -310.34% |
| 2021 | 2.00K | -601.49% |
| 2020 | -398.62 | -438.38% |
| 2019 | 117.80 | -82.37% |
| 2018 | 668.05 | 0.25% |
| 2017 | 666.36 | 407.88% |
| 2016 | 131.20 | -51.92% |
| 2015 | 272.88 | -39.48% |
| 2014 | 450.91 | 82.58% |
| 2013 | 246.96 | -52.23% |
| 2012 | 517.00 | 0.00% |
類似企業や競合他社のP/E比率
| 企業 | P/E比率 | P/E比率の差 | 国 |
|---|---|---|---|
| 33.11 | -57.70% |
US
|
|
| 21.39 | -72.67% |
IE
|
|
| 28.94 | -63.02% |
US
|
|
| 17.34 | -77.85% |
US
|
|
| - | - |
DE
|
P/E比率の読み方
株価収益率（P/E Ratio）は、企業の株価と1株あたり利益の関係を示します。
低いが正のP/Eは、現在の評価額に対して高い利益を上げている企業を示し、割安と見なされる可能性があります。高い負の（0に近い）P/Eは、損失が大きいことを示します。
P/Eが30を超えるか、負である企業は一般に「成長株」と見なされ、投資家は将来的な成長または黒字化を期待しています。
10未満の正のP/Eを持つ企業は一般に「割安株」と見なされ、既に収益性が高いが成長の余地は小さいと見なされます。